Aurélie Estienney
About Aurélie Estienney
Aurélie Estienney is the Associate Director of Operational Excellence in Immuno-oncology and Haematology at Bristol-Myers Squibb, with extensive experience in the oncology sector and a diverse educational background.
Current Position at Bristol-Myers Squibb
Aurélie Estienney currently holds the position of Associate Director Operational Excellence in Immuno Oncology and Haematology at Bristol-Myers Squibb in New Jersey, United States. She has been with the company for over 9 years, starting in February 2014. Her role involves optimizing operational processes within the immuno-oncology and haematology sectors.
Previous Roles at Novartis
Aurélie Estienney worked at Novartis for four years. From 2012 to 2014, she served as Brand Manager, Oncology in Basel, Basel-city, Switzerland. Prior to that, she was a Bpa Manager R and D Oncology from 2010 to 2012, also based in Basel. During her tenure, she gained substantial experience in the oncology sector, contributing to her expertise in pharmaceutical operations.
Earlier Career Experience
Before her tenure at Novartis, Aurélie Estienney worked at Sodexo as a Global Supply Chain - Financial Analyst from 2009 to 2010 in France. She also held the position of Operational Controller - R and D at L'Oréal in Paris, Île-de-france, France from 2007 to 2008. These roles enhanced her proficiency in financial analysis and operational control.
Educational Background
Aurélie Estienney has a comprehensive educational background. She studied at Emlyon Business School in 2015. From 2005 to 2008, she achieved her Masters in Management and Entrepreneurship from Edhec Business School. Earlier, she studied Social Sciences at Université Paris Dauphine - Psl from 2003 to 2005. These institutions are prestigious and have contributed significantly to her professional qualifications.
International Pharmaceutical Experience
Aurélie Estienney's career includes significant international experience in the pharmaceutical industry, particularly in Switzerland while working for Novartis. Her roles have provided her with a global perspective and deep understanding of the oncology sector, reflected in her current responsibilities at Bristol-Myers Squibb.